Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study

Jan Benes, Roman Skulec, Jakub Jobanek, Vladimir Cerny, Jan Benes, Roman Skulec, Jakub Jobanek, Vladimir Cerny

Abstract

Background: Deep vein thrombosis (DVT) is a serious but preventable complication of critical illness with a reported incidence from 4 to 17%. Anti-Xa activity in critically ill patients achieved with standard dosing of low-molecular-weight heparins (LMWH) is often below the target of 0.2-0.5 IU/mL. However, the clinical significance of this finding is unclear. The quality of thromboprophylaxis also strongly impacts the incidence of DVT. We performed a prospective observational study to evaluate the incidence of DVT in a mixed medical-surgical-trauma intensive care unit (ICU) using a thromboprophylaxis protocol with a fixed dose of enoxaparin. We also explored the relation between DVT incidence and anti-Xa activity.

Method: All consecutive patients with expected ICU stay ≥72 hours and without evidence of DVT upon admission were included. They underwent ultrasound screening for DVT twice a week until ICU discharge, death, DVT or pulmonary embolism. Peak anti-Xa activity was measured twice a week. Patients received 40 mg of enoxaparin subcutaneously (60 mg in obese, 20 mg in case of renal failure). Graduated compression stockings were used in case of LMWH or another anticoagulant contraindication.

Results: A total of 219 patients were enrolled. We observed six cases of DVT (incidence of 2.7%). The agreement between expected and delivered DVT prophylaxis was 94%. Mean peak anti-Xa activity level was 0.24 (SD, 0.13) IU/mL. There was no significant difference in anti-Xa activity in DVT and non-DVT group.

Conclusion: A low incidence of DVT was achieved with meticulous adherence to the standard prophylactic protocol. The low incidence of DVT was observed despite low levels of anti-Xa activity. Our findings suggest that enoxaparin dose adjustment based on regular monitoring of anti-Xa activity is unlikely to result in further reduction of DVT incidence in a mixed ICU population.

Trial registration: ClinicalTrials.gov, NCT03286985.

Keywords: anti-Xa; compression ultrasound test; enoxaparin; pulmonary embolism; thromboprophylaxis intensive care units; venous thrombosis.

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161(4 Pt 1):1109-14. doi:10.1164/ajrccm.161.4.9807025
    1. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011;364(14):1305-14. doi:10.1056/NEJMoa1014475
    1. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005;33(7):1565-71. doi:10.1097/01.ccm.0000171207.95319.b2
    1. Skrifvars MB, Bailey M, Presneill J, French C, Nichol A, Little L, Duranteau J, Huet O, Haddad S, Arabi Y, McArthur C, Cooper DJ, Bellomo R, EPO-TBI investigators and the ANZICS Clinical Trials Group. Venous thromboembolic events in critically ill traumatic brain injury patients. Intensive Care Med 2017;43(3):419-28. doi:10.1007/s00134-016-4655-2
    1. Boddi M, Barbani F, Abbate R, Bonizzoli M, Batacchi S, Lucente E, Chiostri M, Gensini GF, Peris A. Reduction in deep vein thrombosis incidence in intensive care after a clinician education program. J Thromb Haemost 2010;8(1):121-28. doi:10.1111/j.1538-7836.2009.03664.x
    1. Karcutskie CA, Dharmaraja A, Patel J, Eidelson SA, Padiadpu AB, Martin AG, Lama G, Lineen EB, Namias N, Schulman CI, Proctor KG. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. JAMA Surg 2018;153(2):144. doi:10.1001/jamasurg.2017.3787
    1. Connelly CR, Van PY, Hart KD, Louis SG, Fair KA, Erickson AS, Rick EA, Simeon EC, Bulger EM, Arbabi S, Holcomb JB, Moore LJ, Schreiber MA. Thrombelastography-based dosing of enoxaparin for thromboprophylaxis in trauma and surgical patients: A randomized clinical trial. JAMA Surg 2019;151(10): e162069. doi:10.1001/jamasurg.2016.2069
    1. Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, Mandourah Y, Almekhlafi GA, Almaani M, Al Bshabshe A, Finfer S, Arshad Z, Khalid I, Mehta Y, Gaur A, Hawa H, Buscher H, Lababidi H, Al Aithan A, Abdukahil SAI, Jose J, Afesh LY, Al-Dawood A. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med 2019;380(14):1305-15. doi:10.1056/NEJMoa1816150
    1. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, Cartier J-C, Ferretti G, Schwebel C, Timsit J-F, Perkins G, McAuley D, Davies S, Gao F, McLeod A, Geerts W, Konstantinides S, Moser K, LeMoine J, Nachtwey F, Spragg R, Cade J, Kapoor M, Kupfer Y, Tessler S, Fraisse F, Holzapfel L, Couland J, Simonneau G, Bedock B, Feissel M, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin T, Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Ibrahim E, Iregui M, Prentice D, Sherman G, Kollef M, Shannon W, Harris L, Curl G, Booth F, Hassett J, Leney G, Ricotta J, Hirsch D, Ingenito E, Goldhaber S, Schultz D, Brasel K, Washington L, Goodman L, Quickel R, Lipchik R, Patel R, Cook D, Meade M, Griffith L, Mehta G, Rocker G, Bahloul M, Chaari A, Kallel H, Abid L, Hamida C, Dammak H, Bahloul M, Chaari A, Dammak H, Medhioub F, Abid L, Ksibi H, Minet C, Lugosi M, Savoye P, Menez C, Ruckly S, Bonadona A, Goldhaber S, Visani L, Rosa M, Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Wells P, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care 2015;19(1):287. doi:10.1186/s13054-015-1003-9
    1. Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Nybo M, Rasmussen B, Toft P. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Crit Care 2013;17(2):R75. doi:10.1186/cc12684
    1. Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, Barrios C, Hoyt DB. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010;68(4):874-80. doi:10.1097/TA.0b013e3181d32271
    1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S. doi:10.1378/chest.1412S3
    1. Costantini TW, Min E, Box K, Tran V, Winfield RD, Fortlage D, Doucet J, Bansal V, Coimbra R. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg 2013;74(1):128-33; discussion 134-5. doi:10.1097/TA.0b013e3182788fa7
    1. Singer GA, Riggi G, Karcutskie CA, Vaghaiwalla TM, Lieberman HM, Ginzburg E, Namias N, Lineen EB. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg 2016;81(6):1101-08. doi:10.1097/TA.0000000000001193
    1. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann J-F. Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients. N Engl J Med 2011;365(26):2463-72. doi:10.1056/NEJMoa1111288
    1. Wei MY, Ward SM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep 2015;7(4):80-83. doi:10.4081/hr.2015.5844
    1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3(4):692-94. doi:10.1111/j.1538-7836.2005.01204.x
    1. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8(1):202-4. doi:10.1111/j.1538-7836.2009.03678.x
    1. Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. JAMA Surg 2016;151(11):1006. doi:10.1001/jamasurg.2016.1662

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj